Description
Ciclosporin Alcaloidsoft (ciclosporin) Capsules 50 mg. №50
Ingredients
Active ingredient: Ciclosporin 50 mg.
Dosage
Dosage: The usual starting dose is 2.5 mg/kg/day divided into two doses. Dosage may vary based on individual patient factors.
Indications
Indications: Ciclosporin Alcaloidsoft is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants.
Contraindications
Contraindications: Do not use in patients with a hypersensitivity to ciclosporin or any component of the formulation.
Directions
Directions: Take Ciclosporin Alcaloidsoft capsules orally, usually twice daily, at the same times each day. Do not crush or chew the capsules.
Pharmacological Properties
Ciclosporin, the active ingredient in Ciclosporin Alcaloidsoft, is a potent immunosuppressive agent that acts by inhibiting the production and release of interleukin-2 and other cytokines essential for T-cell activation. This mechanism helps prevent organ rejection in transplant patients.
Benefits and Comparisons
Ciclosporin Alcaloidsoft offers a reliable option for transplant patients requiring immunosuppressive therapy. Its well-established pharmacological effects and proven efficacy make it a valuable choice in preventing organ rejection and improving patient outcomes post-transplant.
Suitable Patient Groups
This medication is suitable for a wide range of patient groups, including adults, children, and the elderly undergoing kidney, liver, or heart allogeneic transplants.
Storage and Shelf Life
- Storage: Store at room temperature away from light and moisture.
- Shelf Life: Check the expiration date on the packaging and do not use the product after that date.
Packaging Description
The product is available in blister packs containing 50 capsules of 50 mg each.
Side Effects
Common side effects of Ciclosporin Alcaloidsoft may include hypertension, nephrotoxicity, tremor, and hypertrichosis. Patients should consult their healthcare provider if they experience any adverse reactions.
Clinical Evidence
Several studies have demonstrated the efficacy of ciclosporin in improving graft survival rates and reducing the incidence of acute rejection episodes in transplant recipients. For example, a study published in the American Journal of Transplantation showed that ciclosporin-based immunosuppression significantly improved long-term outcomes in kidney transplant patients.
